IMPLANTABLE PUMP OPTION Sample Clauses

IMPLANTABLE PUMP OPTION. 6 3.9 DETERMINATION THAT DEVELOPMENT PROGRAM IS UNFEASIBLE.............7 3.10 SALES, MARKETING AND DISTRIBUTION................................7 3.11
AutoNDA by SimpleDocs
IMPLANTABLE PUMP OPTION. DBT shall give written notice to IMT of both the submission of the DBT Pump for FDA Approval, and the FDA Approval. During the period commencing on the sooner of (i) the submission of the DBT Pump for FDA Approval and (ii) the date on which DBT gives written notice to IMT that it is prepared to commence a development program for an implantable insulin pump, and ending on the sooner of (i) three months after DBT has given notice to IMT of FDA Approval and (ii) the date which is the later of 5 years after the date of this Agreement or nine months after DBT has given notice to IMT that it is prepared to commence a development program for an implantable insulin pump, IMT shall have the option (the "IMPLANTABLE OPTION") of entering into the Development and Licensing Agreement (the "IMPLANTABLE PUMP AGREEMENT") with DBT attached hereto as Exhibit C. During the period that IMT is entitled to exercise such option, DBT and IMT shall attempt to agree on the specifications for the implantable pump to be developed pursuant to such agreement, and the milestones for the development program to be undertaken by DBT under such agreement. At least 45 days prior to the expiration of the Implantable Option, DBT shall give written notice to IMT of the specifications (the "OFFERED SPECIFICATIONS") on which DBT wishes to be able to develop an implantable insulin pump for third parties in the event that IMT does not exercise the Implantable Option. IMT shall be entitled to include the Offered Specifications as the specification contemplated by the Implantable Pump Agreement and exercise the Implantable Option on that basis. If IMT fails to do so, and IMT and DBT do not enter into the Implantable Pump Agreement with other specifications, then, except as provided below in this Section 3.8, during the one year period (the "OPEN PERIOD") following the delivery by DBT of the Offered Specifications, DBT shall be entitled to enter an agreement (a "THIRD PARTY AGREEMENT") with a third party to develop and commercialize an implantable insulin pump based on the Offered Specifications on terms and conditions which are at least as favorable to DBT in all material respects as the terms specified in the Implantable Pump Agreement. If the DBT Intellectual Property changes in any material respect between the date on which DBT has last updated IMT in writing regarding the status of the DBT Intellectual Property which date occurs not later than 15 days after the delivery of the Offered Specificati...

Related to IMPLANTABLE PUMP OPTION

  • Top-Up Option (a) The Company hereby grants to Parent and Merger Sub an irrevocable option (the “Top-Up Option”) to purchase, at a price per Share equal to the Offer Price, up to such number of Shares (the “Top-Up Option Shares”) that, when added to the number of Shares owned by Parent and Merger Sub and any wholly owned Subsidiary of Parent or Merger Sub immediately prior to the time of exercise of the Top-Up Option, constitutes one Share more than 80% of the number of Shares that will be outstanding on a fully diluted basis immediately after the issuance of the Top-Up Option Shares. The Top-Up Option will be exercised by Parent or Merger Sub immediately after the Acceptance Time if following such Acceptance Time, Parent or Merger Sub do not own 80% of the outstanding Shares; provided, however, that the obligation of the Company to deliver Top-Up Option Shares upon the exercise of the Top-Up Option is subject to the conditions that (i) no judgment, injunction, order or decree of any Governmental Entity shall prohibit the exercise of the Top-Up Option or the delivery of the Top-Up Option Shares in respect of such exercise, (ii) the issuance of the Top-Up Option Shares will not cause the Company to have more Shares outstanding than are authorized by the Restated Articles of Incorporation of the Company, and (iii) Merger Sub has accepted for payment and paid for all Shares validly tendered in the Offer and not withdrawn. The parties shall cooperate to ensure that the issuance of the Top-Up Option Shares is accomplished consistent with all applicable legal requirements of all Governmental Entities, including compliance with an applicable exemption from registration of the Top-Up Option Shares under the Securities Act.

  • Stock Option The Corporation hereby grants to the Optionee the option (the "Stock Option") to purchase that number of shares of Class A Common Stock of the Corporation, par value $.01 per share, set forth on Schedule A. The Corporation will issue these shares as fully paid and nonassessable shares upon the Optionee's exercise of the Stock Option. The Optionee may exercise the Stock Option in accordance with this Agreement any time prior to the tenth anniversary of the date of grant of the Stock Option evidenced by this Agreement, unless earlier terminated according to the terms of this Agreement. Schedule A sets forth the date or dates after which the Optionee may exercise all or part of the Stock Option, subject to the provisions of the Plan.

  • Manufacture (a) Manufacturer shall only manufacture the specific number of Products as requested by Company and at no time shall manufacture excess goods or overruns. Manufacturer shall not sell any Products bearing the Trademarks to any third parties without the express written consent of Company.

  • Second Option If Tenant exercises the First Option, Landlord grants Tenant an additional option (the "Second Option") to extend the term of the Lease for one (1) additional term of five (5) years (the "Second Option Term"). The Second Option applies only to the Premises and is on the following conditions:

  • Manufacturing License Subject to the terms of this Agreement, including without limitation Section 2.2, Theravance grants to GSK an exclusive license under the Theravance Patents and Theravance Know-How to make and have made API Compound or formulated Alliance Product in the Territory.

  • Partial Exercise; Effective Date of Exercise In case of any partial exercise of this Warrant, the Company shall cancel this Warrant upon surrender hereof and shall execute and deliver a new Warrant of like tenor and date for the balance of the shares of Common Stock purchasable hereunder. This Warrant shall be deemed to have been exercised immediately prior to the close of business on the date of its surrender for exercise as provided above. The person entitled to receive the shares of Common Stock issuable upon exercise of this Warrant shall be treated for all purposes as the holder of record of such shares as of the close of business on the date the Company receives the Notice of Exercise, subject to receipt of the Exercise Amount.

  • Adjustments in Option The Committee shall make adjustments with respect to the Option in accordance with the provisions of Section 9.3 of the Plan.

  • Nonqualified Stock Option The Option is a nonqualified stock option and is not, and shall not be, an incentive stock option within the meaning of Section 422 of the Code.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Non-Qualified Stock Option This Option is not intended to be an “incentive stock option” within the meaning of Section 422 of the Internal Revenue Code and will be interpreted accordingly.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!